AU2021393456A1 - Immunoglobuline constructs with multiple binding domains - Google Patents
Immunoglobuline constructs with multiple binding domains Download PDFInfo
- Publication number
- AU2021393456A1 AU2021393456A1 AU2021393456A AU2021393456A AU2021393456A1 AU 2021393456 A1 AU2021393456 A1 AU 2021393456A1 AU 2021393456 A AU2021393456 A AU 2021393456A AU 2021393456 A AU2021393456 A AU 2021393456A AU 2021393456 A1 AU2021393456 A1 AU 2021393456A1
- Authority
- AU
- Australia
- Prior art keywords
- molecule
- linker
- cell
- amino acids
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121166P | 2020-12-03 | 2020-12-03 | |
| US63/121,166 | 2020-12-03 | ||
| PCT/US2021/061587 WO2022120033A1 (en) | 2020-12-03 | 2021-12-02 | Immunoglobuline constructs with multiple binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021393456A1 true AU2021393456A1 (en) | 2023-06-29 |
| AU2021393456A9 AU2021393456A9 (en) | 2024-09-26 |
Family
ID=79170974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021393456A Pending AU2021393456A1 (en) | 2020-12-03 | 2021-12-02 | Immunoglobuline constructs with multiple binding domains |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250277024A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4255931A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7886869B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230117397A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116783217A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021393456A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3203468A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303205A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006573A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022120033A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023268600A1 (en) * | 2022-05-12 | 2024-11-07 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
| WO2026152120A2 (en) | 2025-01-13 | 2026-07-16 | HCW Biologics, Inc. | Chimeric polypeptides and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| DE19650370A1 (de) | 1996-12-05 | 1998-06-10 | Basf Ag | Flammwidrige thermoplastische Formmassen auf der Basis von Polyarylenethern |
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EA015363B1 (ru) | 2003-07-18 | 2011-06-30 | Эмджен Инк. | Агенты, специфически связывающие фактор роста гепатоцитов, и их применение |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| CA2560889A1 (en) | 2004-03-23 | 2005-10-13 | Sanjay D. Khare | Monoclonal antibodies specific for human ox40l (cd 134l) |
| EP1776383B1 (en) | 2004-07-22 | 2014-08-20 | Erasmus University Medical Center Rotterdam | Binding molecules |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| KR100609578B1 (ko) | 2004-12-28 | 2006-08-08 | 주식회사 하이닉스반도체 | 플래쉬 메모리소자의 플로팅 게이트전극 형성방법 |
| GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
| TWI404727B (zh) | 2006-01-25 | 2013-08-11 | 荷蘭鹿特丹Erasmus大學醫學中心 | 對偶基因排除 |
| PL2155788T3 (pl) | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| GB0706628D0 (en) | 2007-04-04 | 2007-05-16 | Univ Erasmus | Germ-line manipulation 1 |
| WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
| KR101711222B1 (ko) | 2008-12-18 | 2017-02-28 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| EP2938637A2 (en) | 2012-12-28 | 2015-11-04 | AbbVie Inc. | Multivalent binding protein compositions |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| WO2014151910A1 (en) * | 2013-03-15 | 2014-09-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| EP3774914A2 (en) * | 2018-04-13 | 2021-02-17 | Affimed GmbH | Nk cell engaging antibody fusion constructs |
-
2021
- 2021-12-02 MX MX2023006573A patent/MX2023006573A/es unknown
- 2021-12-02 JP JP2023533306A patent/JP7886869B2/ja active Active
- 2021-12-02 IL IL303205A patent/IL303205A/en unknown
- 2021-12-02 CA CA3203468A patent/CA3203468A1/en active Pending
- 2021-12-02 US US18/038,886 patent/US20250277024A1/en active Pending
- 2021-12-02 CN CN202180081858.3A patent/CN116783217A/zh active Pending
- 2021-12-02 EP EP21835502.2A patent/EP4255931A1/en active Pending
- 2021-12-02 WO PCT/US2021/061587 patent/WO2022120033A1/en not_active Ceased
- 2021-12-02 KR KR1020237022372A patent/KR20230117397A/ko active Pending
- 2021-12-02 AU AU2021393456A patent/AU2021393456A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116783217A (zh) | 2023-09-19 |
| AU2021393456A9 (en) | 2024-09-26 |
| US20250277024A1 (en) | 2025-09-04 |
| WO2022120033A1 (en) | 2022-06-09 |
| JP2023553384A (ja) | 2023-12-21 |
| JP7886869B2 (ja) | 2026-07-08 |
| KR20230117397A (ko) | 2023-08-08 |
| EP4255931A1 (en) | 2023-10-11 |
| IL303205A (en) | 2023-07-01 |
| CA3203468A1 (en) | 2022-06-09 |
| MX2023006573A (es) | 2023-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12441798B2 (en) | CD123 binding proteins and related compositions and methods | |
| JP6807890B2 (ja) | 抗cd40抗体および使用方法 | |
| EP3464367B1 (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
| JP2022191360A (ja) | 抗cd40抗体および使用方法 | |
| AU2013318147B2 (en) | Methods for identifying antibodies with reduced immunogenicity | |
| EP3023437A1 (en) | Bispecific antibodies against CD3epsilon and BCMA | |
| JP2021511808A (ja) | 抗ctla4抗体ならびにその作製及び使用方法 | |
| JP2022533538A (ja) | T細胞媒介性免疫を調節するための材料及び方法 | |
| JP2019534292A (ja) | 組み合わせた抗cd40抗体および使用方法 | |
| JP7618592B2 (ja) | 選択的に切断可能なリンカーを有する二重特異性結合構築物 | |
| US20250277024A1 (en) | Molecules with multiple binding domains | |
| US20230203198A1 (en) | Bispecific binding constructs | |
| WO2024148328A9 (en) | Bispecific pd-l1 and cd40 binding molecules and uses thereof | |
| WO2025209593A1 (zh) | 一种多特异性抗体t细胞衔接器 | |
| TW202602945A (zh) | 抗gucy2c抗體及其多特異性抗體的用途 | |
| WO2026050570A1 (en) | Engineered protein constructs targeting siglec-8 and cd117 | |
| EA047733B1 (ru) | Cd123-связывающие белки и относящиеся к ним композиции и способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |